StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a report published on Sunday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Stock Up 3.3 %
Evoke Pharma stock opened at $5.30 on Friday. The firm’s fifty day moving average is $4.77 and its 200 day moving average is $5.51. Evoke Pharma has a 12-month low of $3.54 and a 12-month high of $17.88. The company has a market capitalization of $4.35 million, a PE ratio of -0.33 and a beta of 0.39.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last issued its earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). The firm had revenue of $2.55 million during the quarter. Evoke Pharma had a negative return on equity of 964.25% and a negative net margin of 86.74%.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
See Also
- Five stocks we like better than Evoke Pharma
- Why is the Ex-Dividend Date Significant to Investors?
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- The 3 Best Fintech Stocks to Buy Now
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What is the NASDAQ Stock Exchange?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
